Clinical Trial: GT719 Injection for Moderate to Severe Refractory Autoimmune Disease

U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07132112) titled 'GT719 Injection for Moderate to Severe Refractory Autoimmune Disease' on Aug. 14.

Brief Summary: This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune disease. A total of 30 subjects will be enrolled in this study.

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Auto Immune Disease

Intervention: BIOLOGICAL: GT719 Injection

GT719 Injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Grit Biotechnology...